Literature DB >> 23674310

Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.

Ioannis Karalis1, Patrick C N Rensen, J Wouter Jukema.   

Abstract

Entities:  

Keywords:  atherosclerosis; high-density lipoprotein; lipids and lipoprotein metabolism

Mesh：

Substances：

Year:  2013        PMID： 23674310     DOI： 10.1161/CIRCOUTCOMES.111.000014

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN： 1941-7713


× No keyword cloud information.
  4 in total

1.  Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.

Authors:  Sam J L van der Tuin; Susan Kühnast; Jimmy F P Berbée; Lars Verschuren; Elsbet J Pieterman; Louis M Havekes; José W A van der Hoorn; Patrick C N Rensen; J Wouter Jukema; Hans M G Princen; Ko Willems van Dijk; Yanan Wang
Journal:  J Lipid Res       Date:  2015-09-04       Impact factor: 5.922

2.  Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.

Authors:  Susan Kühnast; Sam J L van der Tuin; José W A van der Hoorn; Jan B van Klinken; Branko Simic; Elsbet Pieterman; Louis M Havekes; Ulf Landmesser; Thomas F Lüscher; Ko Willems van Dijk; Patrick C N Rensen; J Wouter Jukema; Hans M G Princen
Journal:  Eur Heart J       Date:  2014-08-20       Impact factor: 29.983

Review 3.  HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?

Authors:  I Karalis; J W Jukema
Journal:  Curr Cardiol Rep       Date:  2018-06-21       Impact factor: 2.931

Review 4.  Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.

Authors:  Bishnu H Subedi; Parag H Joshi; Steven R Jones; Seth S Martin; Michael J Blaha; Erin D Michos
Journal:  Vasc Health Risk Manag       Date:  2014-04-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.